Australia Antacids Market Overview, 2031

Key Insights

• According to the research report, "Australia Antacids Market Outlook, 2031," published by Bonafide Research, the Australia Antacids Market is expected to reach a market size of more than 11.9 Million by 2031.
• Traditional single-action mineral antacids (e.g., standard calcium carbonate or magnesium hydroxide alone) are losing market share to dual-action alginate-based formulations. The most significant formulation innovation in Australia has been the widespread consumer adoption of dual-action alginates combined with antacids (pioneered by brands like Gaviscon Dual Action). Rather than simply buffering gastric acid, these formulations create a protective liquid raft that floats atop stomach contents to physically block acid reflux into the esophagus while simultaneously neutralizing excess acid.
• In Australia, the Pharmaceutical Benefits Scheme (PBS) and the Therapeutic Goods Administration (TGA), alongside clinical initiatives like Choosing Wisely Australia, have placed strong emphasis on de-prescribing long-term Proton Pump Inhibitors (PPIs) for mild or uncomplicated Gastro-oesophageal Reflux Disease (GORD). General Practitioners (GPs) are actively encouraging step-down therapies for long-term PPI users. This regulatory shift has successfully redirected mild-to-moderate sufferers back toward OTC antacids, alginates, and rapid-acting H2 receptor antagonists (such as famotidine) for symptom-driven, episodic relief.
• Australian consumers show a strong preference for health-conscious, clean-label over-the-counter products. Health-conscious purchasing trends have spurred major product line expansions, including low-sodium and sugar-free antacids targeted at Australia's aging demographic and cardiovascular-conscious patients.

Market Outlook

• Digital pharmacy fulfillment and online OTC ordering continue to grow rapidly in Australia, expanding access to non-prescription acid-reduction remedies and drive-to-door OTC delivery. Next-generation OTC offerings in Australia are expected to increasingly pair immediate acid-neutralizing agents with mucosal repair ingredients (e.g., zinc carnosine or botanical extracts) and gut-microbiome supportive ingredients to offer combined immediate and long-term digestive care.
• The regulatory and clinical environment in Australia is guided by the Therapeutic Goods Administration (TGA), Consumer Healthcare Products Australia (CHP Australia), and the Gastroenterological Society of Australia (GESA), with market supply led by major domestic and international pharmaceutical leaders including Reckitt Benckiser (Gaviscon), Bayer Australia (Rennie, Mylanta), Haleon, Sanofi, and Johnson & Johnson / Kenvue (Mylanta range variants).

Market Dynamics

Driver: Growing consumer focus on gut health and digestive wellness
A key driver for Australia's antacids market is the increasing consumer focus on gut health and digestive comfort. Australian consumers are becoming more proactive about identifying and managing digestive issues, with awareness extending beyond immediate symptom relief toward broader gut health and wellbeing. Euromonitor reports that heightened awareness of gut health supported growth in digestive remedies in 2025, alongside increased spending on products addressing gastrointestinal health. An ageing population, lifestyle changes and growing public awareness are also supporting demand.
Challenge: Strong competition from alternative digestive remedies and established brands
The Australian market is relatively mature and competitive. Consumers have access to antacids alongside H2 blockers, proton-pump inhibitors (PPIs), antiflatulents, digestive enzymes and other digestive remedies, creating substitution pressure within the broader heartburn and indigestion category. Euromonitor specifically reports that Australian shoppers tend to stick to tried-and-tested brands, which makes it harder for new antacid brands to gain shelf space and consumer recognition.
Trend: Expansion of premium and complementary digestive-health solutions
A notable trend is the movement from basic symptom treatment toward broader, more specialized digestive-health solutions. Australian consumers are increasingly interested in products supporting digestive comfort and gut health, while newer consumer-health trends are opening opportunities for complementary products. Euromonitor identifies the growing use of GLP-1 medications as one emerging opportunity because these medicines can create gastrointestinal side effects and associated demand for complementary digestive products.

Procurement and Industry Impact

• Australian pharmaceutical procurement faces exposure to manufacturing disruptions, ingredient shortages, international supply chains and trade restrictions. Australia's TGA states that medicine shortages can result from manufacturing delays, supply-chain problems, regulatory barriers, trade limitations and unexpected demand increases. Suppliers are required to report shortages for relevant prescription and non-prescription medicines.
• All medicines supplied in Australia must meet applicable regulatory and quality requirements, while manufacturers/importers are responsible for maintaining product quality throughout production, supply, transport and distribution. For antacid manufacturers, this increases the importance of qualified suppliers for APIs, excipients, packaging materials and contract manufacturing. A low-cost supplier that creates quality or regulatory problems can ultimately be more expensive because of rejected batches, additional testing, recalls or supply interruptions.
• Australia's digestive-remedy market is strongly dependent on pharmacies and supermarkets, which Euromonitor identifies as the dominant sales channels. This gives major retailers significant influence over product placement, promotions, pricing and inventory requirements. Manufacturers need procurement strategies that support large-volume production, competitive unit economics and reliable retailer fulfillment. Packaging optimization is particularly relevant because products must meet retailer requirements while remaining attractive and affordable to consumers.

Segment Analysis

Australia Antacids Market By Drug Class
• Acid neutralizers remain an important option for occasional heartburn, indigestion and acid-related discomfort because they work directly on gastric acid already present in the stomach. Calcium-, magnesium- and aluminium-based formulations are used for rapid symptomatic relief. Australia's TGA explicitly identifies antacids as OTC medicines, while its regulatory framework allows some non-prescription medicines to be sold through pharmacies, supermarkets or other approved channels depending on their risk classification.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position because they reduce gastric acid production rather than simply neutralizing existing acid. In Australia, some PPI products have been positioned for pharmacy-based treatment of heartburn and acid reflux. The TGA specifically gives esomeprazole tablets/capsules for heartburn and acid reflux as an example of a pharmacy medicine, illustrating the controlled-access position of some acid-suppressive products.
• H2 antagonists provide another acid-suppression mechanism and are positioned between immediate symptomatic antacids and longer-acting PPIs. They can be useful for consumers requiring acid reduction for episodic symptoms. Australia's regulatory history also distinguishes H2-receptor antagonists from antacids in the treatment of frequent heartburn, with earlier TGA documentation describing antacids as primarily intended for occasional use and H2 antagonists as suitable for as-needed or short-duration treatment.
• Pro-motility agents represent a specialized segment because their principal therapeutic action is on gastrointestinal movement rather than acid neutralization or suppression. They may be relevant when reflux symptoms coexist with delayed gastric emptying or other motility disturbances. Their role is consequently more clinically directed than conventional Australian OTC antacid consumption.
• Combination formulations are particularly useful when consumers experience several upper-GI symptoms simultaneously, such as heartburn, acid reflux and gas. Antacid-alginate combinations can provide both acid neutralization and a physical reflux-barrier mechanism, while combinations containing simethicone can address gas-related discomfort. The TGA's OTC framework specifically recognizes medicines containing locally acting ingredients such as simethicone and alginic acid, supporting their relevance within Australia's gastrointestinal product landscape.

Australia Antacids Market By Dosage Form
• Tablets and chewables are well suited to Australia's self-care environment because they provide portable, standardized dosing and can be taken without measuring equipment. Chewable antacids are particularly convenient after meals, during travel or at work. Their simple administration also makes them appropriate for symptom-driven purchases through pharmacies and other permitted OTC channels.
• Liquid suspensions provide an alternative for consumers who have difficulty swallowing tablets or prefer liquid medicines. They allow flexible combinations of aluminium, magnesium and other active ingredients. Product consistency, accurate measuring, flavour and stability are important competitive factors because these characteristics directly influence the consumer experience.
• Powders offer a flexible non-tablet format that can be dispersed or dissolved before administration. They can appeal to consumers looking for convenient single-dose preparations, although the need for preparation makes them somewhat less convenient than ready-to-use liquids or chewables. Sachet design, moisture protection and clear dosage instructions therefore become important differentiating factors.
• Gels and syrups provide smooth administration and are particularly suitable for formulations designed around reflux-barrier mechanisms. Alginate-containing products can form a protective layer that helps reduce reflux of gastric contents into the oesophagus. This gives gel-like products a functional advantage beyond simple acid neutralization.
• Gummies and other formats represent a more consumer-oriented opportunity in Australia's gastrointestinal self-care category. Gummies can provide portability and a familiar administration experience, although conventional antacid ingredients may be difficult to incorporate at therapeutically meaningful quantities while preserving taste and texture. Other formats, including effervescent and rapidly dispersible products, can compete through convenience and perceived speed of action.

Australia Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD/GORD) is a major indication supporting Australia's broader acid-control category. Australian clinical literature describes GORD as a condition involving recurrent symptoms or mucosal damage caused by reflux of gastric contents. Australian primary-care guidance also notes that self-medication with OTC preparations, usually antacids, is common, while persistent symptoms may require definitive treatment.
• Heartburn is one of the strongest consumer self-care indications because the symptom is easily recognized and can prompt direct purchase of an OTC product. Australian regulatory guidance identifies antacids among typical OTC medicines and describes OTC medicines as being primarily used for mild health problems. This creates a clear role for rapid-relief antacids in occasional heartburn, while persistent symptoms can move consumers toward pharmacist assessment and acid-suppressive therapy.
• Peptic ulcer represents a more clinically managed indication than routine heartburn. Antacids may reduce acid-related discomfort, but they do not address underlying causes such as H. pylori infection or medication-associated ulceration. Consequently, PPIs and other disease-directed therapies have a more important role in ulcer healing, while antacids are primarily positioned around symptomatic relief.
• Others include dyspepsia, acid indigestion, epigastric discomfort, post-meal fullness and other upper-GI complaints. This segment is particularly relevant to OTC products because consumers may initially interpret symptoms as ordinary indigestion rather than a diagnosed gastrointestinal disorder. Australia's primary-care literature emphasizes the need to distinguish simple indigestion from persistent reflux requiring further assessment.

Australia Antacids Market By Distribution Channel
• Retail pharmacies remain a strategically important channel because pharmacists provide a convenient point for consumers to obtain gastrointestinal medicines while receiving advice about appropriate product selection. Australia's TGA states that some OTC medicines are available directly from pharmacies, while others require consultation with a pharmacist. This makes pharmacist recommendation particularly relevant when consumers are choosing between antacids, H2 antagonists and PPIs.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GORD, reflux complications, peptic ulcers and other gastrointestinal disorders. Demand through this channel is therefore influenced more by physician diagnosis, hospital formularies and treatment protocols than by spontaneous OTC purchasing. Stronger acid-suppressive medicines are particularly relevant in this setting.
• Online pharmacies / E-commerce provide convenience for repeat purchases and allow consumers to compare products, pack sizes and formulations before ordering. However, online supply remains subject to Australia's therapeutic-goods framework. The TGA states that medicines generally must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can legally be supplied, unless an exemption applies.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce